Tag Archives: Daryl Luster

2016 Highlights of a Local Hepatitis C Advocate

2016 Highlights of a Local Hepatitis C AdvocateHepatitis C advocates are essential to bettering the lives of those living with hep C. As we begin 2017, the Hepatitis C Treatment Information Project wanted to look back and highlight some of the 2016 work of Daryl Luster, one of our hep C advocates.

The following is a collection of 2016 articles, events, and resources that Daryl Luster, hep C advocate and president of PHCN, was a part of:

February 11th, 2016

Daryl Luster wrote an editorial about the price of hepatitis C direct-acting antiviral treatments.

February 25 – 28th
The Canadian Network on Hepatitis C’s 5th Canadian Symposium on Hepatitis C Virus

The Canadian Network on Hepatitis C‘s 5th Canadian Symposium on Hepatitis C Virus took place in Montreal, in 2016. It gathered international experts, including Daryl, together to discuss hep C research into topics such as: treatment, immune response, antiviral resistance, HIV co-infected, and hepatitis C prevention and management.

May 11th
14th Annual Genomics Forum – “Global Impacts of Genomics”

This one-day scientific forum brought researchers and collaborators from all of BC’s life sciences sectors together to share information and discuss opportunities for future collaborations. Daryl took part in the event’s afternoon and panel session about global health and spoke about patients, the nexus of healthcare and research.

April 24th

Daryl Luster wrote an opinion piece that was published by The Vancouver Sun about hepatitis C globally and in BC. It spelt out the importance of testing baby boomers and the neurological and gastrointestinal issues that may be caused by the virus.

July 27th, 2016

Daryl Luster wrote an opinion piece that was published by The Vancouver Sun about hepatitis C globally and in BC. It spelt out the importance of testing baby boomers and the neurological and gastrointestinal issues that may be caused by the virus.

October 18-19th
Action Hepatitis Canada BC Regional Meeting

In our continuing commitment to Action Hepatitis Canada (AHC) and in his role on the steering committee and executive with AHC, Daryl was involved with hosting the meetings in BC. These meetings were part of a cross-Canada series of regional meetings in support of member organizations and the hepatitis community.

October 24th

Daryl Luster wrote an editorial about the newness of hepatitis C direct-acting antiviral treatments and the need to cure whole patients instead of just achieving sustained viral responses.

November 15th

Daryl Luster met with BC NDP MLA Shane Simpson. They spoke about the landscape of hepatitis C in BC, local testing shortfalls, and hep C treatments and cures.

December 1st
World AIDS Day Rally in Vancouver

On this year’s World AIDS Day the hep C and HIV communities stood in solidarity and honoured those they have lost and celebrated the contributions made by community based organizations here, across Canada, and the world. Daryl made a speech urging the Public Health Agency of Canada to rethink the decisions made to grants for HIV and HCV organizations.

Thank you Daryl and all of the hep C advocates who worked so hard in 2016 to speak up for those living with hepatitis C!

The PHCN‘s News in Review Newsletter (06/12/16)

The PHCN‘s News in Review Newsletter (06/12/16)Welcome to the Pacific Hepatitis C Network (PHCN)‘s second Hepatitis C News in Review Newsletter. This is where we review all of the major current issues and events around hepatitis C and hep C treatments. It is an email that includes links to our recent blog posts—including links to blog posts about Public Health Agency of Canada funding.

HEALTH CANADA SUMMARY SAFETY REVIEW – DAAs – ASSESSING THE POTENTIAL RISK OF HEPATITIS B VIRUS REACTIVATION

Please click here for more information.

WHAT WOMEN WITH HEPATITIS C EXPERIENCE NEEDS TO BE IMPROVED NOW

“Although our research on the experience of diagnosis was undertaken prior to the present major advances of interferon-free HCV treatment, which have given new hope of speedy and less burdensome treatment, these new treatments alone will not solve the burden of HCV.” (Mitchell, et al. 2016)

Therefore, it is still critical to examine how women with hepatitis C are cared for and then strive to improve that care. The findings of a new study, published in a recent issue of the Canadian Journal of Nursing Research, are interesting and a good start. Click here to read more.

HEPATITIS C ADVOCACY HIGHLIGHTS

Recently the Public Health Agency of Canada (PHAC) announced that community-based projects that lost funding in the October changes to the HIV and Hepatitis C Community Action Fund‘s Letter of Intent (LOI) funding process will now, on a case-by-case basis, have transitional project funding until March 31, 2018. Click here for more information.

On December 1st, World AIDS Day, the HIV and HCV communities stood together in solidarity with organizations who were denied funding going forward as part of the changes to the PHAC Community Action Fund LOI process. More information about the rally is here.

Daryl Luster was at the World AIDS Day rally and wrote and gave a speech entitled: We Have Not Abandoned the Principles or Communities We Serve, Neither Should PHAC.

In addition, November began with Daryl meeting with BC NDP MLA Shane Simpson. They spoke about the landscape of hepatitis C in BC, local testing shortfalls, and hep C treatments and cures. See a picture here.

HEP C HIGHLIGHTS FROM THE CANADIAN DRUG APPROVAL PIPELINE AND THE LIVER MEETING 2016

The Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, was held last month. Exciting and important hep C clinical results were presented. Some of these highlights can be found in the following posts:

For more information about the topics in this newsletter, please click on the links, visit PHCN’s Hepatitis C Treatment Information Project, or email us.

The Pacific Hepatitis C Network‘s News in Review Newsletter

The Pacific Hepatitis C Network‘s News in Review NewsletterWelcome to the Pacific Hepatitis C Network (PHCN)‘s very first hepatitis C news in review newsletter. This is where we review all of the major issues and events around hepatitis C and hep C treatments. It is an email that includes links to all of our recent blog posts—including the blog post about the big news surrounding the hep C treatment Epclusa (generic name: sofosbuvir/velpatasvir).

EPCLUSA RECOMMENDED BY CADTH

Epclusa (generic name: sofosbuvir/velpatasvir), developed by Gilead Sciences Canada, Inc., just passed its Common Drug Review with the release of the Canadian Drug Expert Committee (CDEC) Final Recommendation. Click here to read more about their recommendation sent to the provinces and territories to help them decide on whether or not to cover the treatment and how to cover it.

HEPATITIS C ADVOCACY HIGHLIGHTS

In October, Daryl Luster wrote two blog posts for the Pacific Hepatitis C Network. Daryl is a hep C advocate who is PHCN’s president, a member of the Executive Steering Committee for Action Hepatitis Canada (AHC), a counselor for the Help-4-Hep helpline, and the administrator of multiple peer support groups. In 2010, Daryl was cured of hep C while participating in a clinical trial. The two blog posts he wrote were:

DAAs: Long Term Effects
AHC BC Regional Meeting: October 18-19

HEP C ABSTRACT HIGHLIGHTS TO BE PRESENTED AT THE LIVER MEETING 2016

The Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, will be held in a week. Last year’s meeting drew more than 9,500 international hepatologists and hepatology health professionals to San Francisco to discuss the latest treatments and research for liver diseases. This year, Boston, Massachusetts, will be hosting the meeting and, as always, the meeting promises to be exciting.

To celebrate the meeting and all of the amazing discoveries that will be presented, the Hepatitis C Treatment Information Project wrote the following blog posts summarizing and highlighting some of what will be presented about hep C treatments:

The Liver Meeting 2016 Hep C Abstract Highlights (Part1)
The Liver Meeting 2016 Hep C Abstract Highlights (Part2)
Live Stream Sessions from The Liver Meeting 2016

THE BASICS SERIES

The Basics Series by the Hepatitis C Treatment Information Project is a series of blog posts about the very basics about hep C and hep C treatments. So far, the series has five issues, entitled the following:

For more information about the topics in this newsletter, please click on the links, visit PHCN’s Hepatitis C Treatment Information Project, or email us.

The Price of a Cure

The Price of a CureThe Price of a Cure was written by Daryl Luster. Daryl is a hep C advocate who is PHCN’s president, a member of the Executive Steering Committee for Action Hepatitis Canada, a counselor for the Help-4-Hep helpline, and the administrator of multiple peer support groups. Daryl was cured of hep C in 2010 while participating in a clinical trial.

The Price of a Cure

Since before the new therapies were discovered there was limited access to treatment. Even though as many as 40%-50% of people were attaining SVR/cure with the Interferon and Ribavirin combination, people were not being treated in large numbers. Many waited for new options, hoping for something easier to tolerate with much higher cure rates, but this was not the whole story. There is no question about the difficult side effects that made treating their hep C impossible for some to consider, and many decided not to treat because of what they read and heard from people who did take the perilous leap. Some were told that they did not need to treat because their virus was “not active” and they would die from something else first.

We know this is nonsense now, as we are seeing more people with advanced fibrosis and the consequences of living with HCV over time.

In just a few short years things have changed dramatically. New drug therapies offer a cure for nearly everyone living with chronic hepatitis C. This is an amazing story, and may be one of the most significant discoveries in medicine in decades.

Yet one major theme we have heard since the first entry on the new therapy scene is about cost.

The media has had a field day with the high costs associated with curing people of hep C. We have read and heard about how we will be bankrupted by the high prices, whether part of a public or private payer system. Until recently, less has been reported in the mainstream media about the great benefits of new hep C treatments.

I have chosen personally to focus on the value of curing more people and what the human cost will be if we don’t treat people. Another thing I have spoken and written about is my belief that we will see prices drop in a more competitive market with new drugs coming online.

I remain hopeful that this will happen soon, and will be disappointed if it doesn’t.

I am a believer in the free market, and think that severe regulatory pressure can potentially stifle development or make for more inequity globally, but there are some things that are more important than shareholder profits and free-market ideals. This is one.

In my view, price should not be the greatest determinant in access to care and treatment for any illness, and HCV is no exception. The difficult part is in how we manage, negotiate, and develop policies that assure equitable access.

Highlights of a Hep C Advocate’s 2015

Highlights of a Hep C Advocate’s 2015Hep C advocates are essential to bettering the lives of those living with hep C. As we are just about to ring in 2016, the Hepatitis C Treatment Information Project wanted to look back and highlight some of the 2015 work of one of our hep C advocates.

The following is a collection of 2015 articles, events, and resources that Daryl Luster, hep C advocate and president of PHCN, was a part of:

February 5 – 6 — Toronto, Ontario

Advocacy training and advisory board meetings with representatives from the Canadian Liver Foundation, Hemophilia Society, Canadian Treatment Action Council (CTAC), Action Hepatitis Canada (AHC), HepCBC, as well as other groups from across Canada.

February 10 — Toronto, Ontario
AHC Steering Committee Meeting

Daryl is part of AHC‘s executive. AHC is a group that unites organizations and individuals to focus increased attention on the response to hepatitis B and C.

February 11 – 12 — Toronto, Ontario
A meeting entitled ‘National Deliberative Dialogue on Integrated HCV Programming and Services‘ with CATIE
As part of day two discussions, ‘Addressing Different Realities and Priorities: A Population-Level Discussion’, Daryl presented on the older adult population and participated in a panel discussion.

February 24 — Richmond, British Columbia

A meeting with representatives from UBC’s Faculty of Science regarding PHCN‘s participation in supporting research that impacts the hep C community. Daryl shared his own hep C experience and that of people in the community.

February 24 – 26 — Richmond, British Columbia

PHCN participated in a conference entitled ‘Frontline Support Workers’ Conference‘ put on by Pacific AIDS Network and CATIE.

February 26 – March 1 — Banff, Alberta

AHC‘s executive meeting and CATIE‘s learning institute meetings
The objective of these meetings was to identify key messages and information from a symposium on hep C. Daryl presented on the meeting’s last day.

February 27 — Banff, Alberta

4th Canadian Symposium on HCV
Symposium theme: ‘Strategies to Manage HCV Infection in Canada: Moving Towards a National Action Plan’. Daryl presented in his roles with AHC and PHCN. His talk was entitled ‘The role for Patient Advocacy in building a Canadian HCV action plan‘.

March 12 — Penticton, British Columbia

Penticton’s Healthy Living Fair
Working alongside Kathryn (RN), the Penticton & District Community Resources Society (PDCRS) outreach person for hep C related issues and harm reduction in the district, Daryl spoke to fair attendees and handed out literature about hep C screening and treatment access.

March 23

Daryl was quoted by BC’s Ministry of Health in their news release about Sovaldi and Harvoni.

March 24

Daryl was quoted by The Vancouver Sun and The National Post.

April 2 — Vancouver, British Columbia

Daryl had a letter published by The Vancouver Sun about hepatitis C in BC and the importance of treatment access.

April 14 — Vancouver, British Columbia

Pacific Blue Cross Workplace Health Symposium
Daryl presented with Alnoor Ramji MD FRCP(C), Clinical Associate Professor, Division of Gastroenterology, UBC. They spoke on hep C treatment and management to help employers better understand how to support employees and the benefits new treatment options may offer.

May 7 – 8 — Vancouver, British Columbia

First Nations Health Authority’s Gathering Wisdom VII event

May 9 — Richmond, British Columbia

Daryl presented and participated in a panel discussion at the Richmond Centre for Disability‘s Invisible Illness Awareness Forum.

May — Ottawa, Ontario

Daryl was in Ottawa raising awareness and talking to MPs about hep C, screening guidelines, and new advances in therapies that can now cure hep C.

July 9 — Richmond, British Columbia

PHCN held an Advocacy Training and Planning Day for hepatitis C advocates from around BC.

July 21 — Victoria, British Columbia

Daryl traveled to Victoria to meet with government officials. He left feeling that the day included some good discussions and was very worthwhile.

July 28 — Vancouver, British Columbia

Daryl was quoted by BC’s Ministry of Health about Holkira Pak.

July 28 — Vancouver, British Columbia

World Hepatitis Day 2015
Spoke at the Vancouver World Hepatitis Day event at Creekside Community Centre on False Creek. Dr Darryl Plecas, Parliamentary Secretary to the Minister of Health, also spoke at this event, indicating great awareness of viral hepatitis in BC.

September 2 – 4 — Glasgow, Scotland

World Hepatitis Summit 2015
Daryl attended the World Hepatitis Summit as a representative for Action Hepatitis Canada (AHC). In his AHC role, Daryl presented about AHC and World Hepatitis Day, hosted a lunch for Canadian summit delegates, and took part in a consultation hosted by the Medicines Patent Pool.

September — Present

HepatitisC.net
Daryl started writing for HepatitisC.net. His posts can be read online.

October 13 – 14 — Toronto, Ontario

Action Hepatitis Canada’s Advocacy Meeting
At the meeting Daryl and Cheryl Reitz, from HepC BC, spoke on hep C advocacy in BC.

October 20 — Windsor, England

Advocacy Meeting Sponsored by AbbVie
At this meeting, Daryl represented AHC. He may have been the only person representing those with hep C who has had the disease.

October 21 — Ottawa, Ontario, via webcam

Canadian Institutes of Health Research (CIHR) Lecture
Daryl was invited to speak to CIHR about advocacy as a member of CanHepC, a new group formed to address hep C issues in Canada.

November 11 – 12 — Vancouver, British Columbia

The 2nd International Hepatitis Cure & Eradication Conference
The meeting gathered hepatitis experts from different disciplines to learn how science can influence public policy to work to cure and eliminate hepatitis. Daryl was one of the meeting’s speakers.

December 4

The American Journal of Medicine (AJM)‘s exclusive hepatitis C interview with Daryl was published.

December 4

Daryl was featured in HCV New Drug Research‘s December newsletter.

Thank you Daryl and all of the hep C advocates who worked so hard in 2015 to speak up for those living with hep C!

Deb and Daryl, hep C advocates, at the 2nd International Hepatitis Cure & Eradication Conference, November 11 – 12, 2015.
Deb, PHCN’s Program Manager,  and Daryl at the 2nd International Hepatitis Cure & Eradication Conference, November 11 – 12, 2015. They are standing in the fourth row from the top. (Photo courtesy of the 2nd International Hepatitis Cure & Eradication Conference)

AJM’s Hepatitis C Resource Center

AJM's Hepatitis C Resource CenterThe American Journal of Medicine (AJM)’s Hepatitis C Resource Center is a site made up of peer-reviewed content intended to help healthcare professionals. Its content (videos, article collections, and patient handouts/resources) is divided under five subject headings (Primary Care Providers; Hepatologists, Gastroenterologists & Infectious Disease Specialists; India Healthcare Professionals; Additional Resources; and Resource Center Blog).

Hep C Treatment Information at the AJM’s Hepatitis C Resource Center Includes:

  • Downloadable hep C screening and treatment guidelines from EASL, AASLD, and WHO;
  • PDFs of full-text articles and abstracts divided under the subject headings Editor’s Choice and Additional Readings;
  • Industry information

Hepatitis C Blog (Twitter HepCBlogAJM): The Newest Addition to AJM’s Hepatitis C Resource Center

With an increasing number of patients with hepatitis C, The American Journal of Medicine’s Hepatitis C Blog was created in February to support and foster communication. It was created to help health providers overcome challenges that are associated with increased demand for hep C care. Therefore, its content centers around screening, diagnosing, and treating.

Hepatitis C Treatment Blog Posts

A post that stuck out while skimming the blog posts was Key AASLD 2015 HCV Abstracts: Dr. Lebovics as it highlights a number of additional abstracts not mentioned in other reviews of The Liver Meeting 2015.

Some other blog posts about hep C treatment are:

The latest post is an interview with PHCN’s own Daryl Luster, a hep C advocate and educator. He is a person who lived with hep C, participated in a clinical trial, and was treated and cured.

The American Journal of Medicine (AJM)’s Interview with Daryl Luster

Using a question-answer format, the interview begins with the interviewer asking Daryl to share a bit about himself. Daryl shares about who he is and his convictions about the importance of access to treatment, birth cohort screening, community, and primary care. He shares about his advocacy work and his work with those who have been touched by hepatitis C internationally, Canada, and in America. With the expertise that has come with that, he expresses opinions when asked about subjects such as challenges associated with hepatitis C in the U.S. and treatment costs.

About The American Journal of Medicine (AJM)

The American Journal of Medicine (AJM) is the official journal of the Alliance for Academic Internal Medicine, an elite group made up of chairs of departments of internal medicine at more than 125 medical schools across America. It publishes original clinical research and articles on seminal topics for those interested in internal medicine.

Advocating for those with Hep C Here and Abroad

AdvocatingThis fall, Daryl Luster, hep C advocate and president of PHCN, will be advocating for those with hepatitis C and their support networks here and abroad. The following is a list of the meetings that Daryl is looking forward to being a part of:

October 13-14 — Toronto, Ontario
Action Hepatitis Canada (AHC) Advocacy Meeting
Action Hepatitis Canada is a group that unites organizations and individuals to advocate for increased attention for hepatitis B and C–diseases that negatively affect the quality of life of up to 600,000 Canadians and support networks.
At the meeting Daryl and Cheryl Reitz, from HepC BC, will speak on hep C advocacy in BC.

October 20 — Windsor, England
Advocacy Meeting Sponsored by AbbVie
This meeting will bring together clinicians, policy, and NGO experts from around the world who are working for hepatitis policy change and development. The meeting will examine the World Health Organization’s HCV action plan and will be facilitated by Dr. Rafael Bengoa from the Health Policy program at the Duesto Business School in Spain. Dr. Bengoa develops strategies/action plans for fighting hepatitis and has successfully implemented them in both Spain and Israel.
At this meeting, Action Hepatitis Canada will be represented by two of its executives, Jeff Potts and Daryl Luster. Daryl may be the only person representing those with hep C who has had the disease.

October 21 — Ottawa, Ontario, via webcam
Canadian Institutes of Health Research (CIHR) Lecture
CIHR is the Government of Canada’s health research investment agency. Its mandate is to build scientific knowledge and to translation it into improved health, more effective health services and products, and a strong Canadian health care system.
Daryl has been invited to speak to CIHR about advocacy as a member of CanHepC, a new group formed to address hep C issues in Canada.

November 11 – 12 — Vancouver, BC
The Hepatitis Cure & Eradication Meeting
The Hepatitis Cure & Eradication Meeting will gather hepatitis experts from different disciplines to learn how science can influence public policy to work to cure and eliminate hepatitis.
Daryl will be one of the meeting’s speakers. He will talk about his role as a hep C advocate who has also been a patient.

“I’m not a lone voice, I’m many and our voices are our most powerful weapons.” Malala Yousafzai

World Hepatitis Summit Presentation Slides and Thoughts

World Hepatitis Summit Presentation SlidesWorld Hepatitis Summit presentation slides have just been released online. Topics around hep C treatment range from Treatment and access to drugs to The funding of viral hepatitis to Prevention.

Daryl Luster’s Quote about the World Hepatitis Summit 2015

“The recent World Hepatitis Summit in Scotland gathered people from around the globe; people who are involved in all levels of civil society, governments, science, and medical fields. We were well represented with a strong Canadian delegate presence from across the country.

The take-away message for me and other colleagues attending was that as much as we differ from country to country, we have far more in common in the barriers we face and in the work that we do to address hepatitis C as an important health concern.” –Daryl Luster, PHCN’s president and a member of Action Hepatitis Canada‘s executive, attended the World Hepatitis Summit as a representative for Action Hepatitis Canada (AHC).

World Hepatitis Summit 2015

The World Hepatitis Summit 2015 took place in Glasgow, Scotland, September 2 – 4. Jointly hosted by the World Health Organization (WHO) and the World Hepatitis Alliance (WHA), as well as the Scottish Government, the summit gathered over 600 policy makers, patients, and other key stakeholders, from over 90 countries, in Glasgow to garner political and financial commitments required to tackle hepatitis.

Last year, at the Sixty-seventh World Health Assembly, countries from around the world committed to addressing hepatitis by implementing national strategies. They called upon WHO to create a global hepatitis target setting and monitoring system.

This year, the World Hepatitis Summit supported this initiative by creating a space where strategies and best practices could be shared.

World Hepatitis Summit 2015

World Hepatitis Summit 2015

The World Hepatitis Summit 2015 (#Hepatitis2015) in Glasgow, Scotland, is set to take place September 2 – 4 and PHCN is pleased to announce that our president, Daryl Luster, will be there.

The World Hepatitis Summit 2015 is the first conference of its kind to directly address the global burden of viral hepatitis. Jointly hosted by the World Health Organization (WHO) and the World Hepatitis Alliance (WHA), as well as the Scottish Government, the summit will gather policy makers, patients, and other key stakeholders in Glasgow to garner political and financial commitments required to tackle hepatitis.

Last year, at the Sixty-seventh World Health Assembly, countries from around the world committed to addressing hepatitis by implementing national strategies. They called upon WHO to create a global hepatitis target setting and monitoring system.

This year, the World Hepatitis Summit will support this initiative by creating a space where strategies and best practices can be shared. The summit will provide the opportunity for governments to learn about WHO’s Global Hepatitis Programme and the progress that has been made towards a target setting and monitoring system. In addition, WHO will present its new toolkit to assist governments in the development and implementation of efforts against hepatitis.

Furthermore, the World Hepatitis Summit 2015 will strive for action and commitment from global funders, the pharmaceutical industry, and other important groups to “make real lasting progress in drastically reducing the burden of viral hepatitis.”

Daryl Luster, PHCN’s president and a member of Action Hepatitis Canada‘s executive, is attending the World Hepatitis Summit as a representative for Action Hepatitis Canada (AHC). In his AHC role, Daryl will present about Action Hepatitis Canada and World Hepatitis Day.

Daryl will also host and present at Action Hepatitis Canada’s luncheon for Canadian summit delegates. During the summit, this luncheon will give Canadian delegates an opportunity to discuss advocacy and ways that Canadian hepatitis advocates can support each other and work together towards improving Canada’s response to hepatitis.

Daryl has also been invited to take part in a consultation hosted by the Medicines Patent Pool. The Medicines Patent Pool is a United Nations-backed organization that aims to lower the prices of HIV medicines and facilitate the development of better-adapted HIV medicines through voluntary licensing and patent pooling. The organization is currently studying the feasibility of expanding its work into the field of hepatitis C and seeking the views of people living with hep C, NGOs, and others.

PHCN wishes Daryl and all of the World Hepatitis Summit 2015 delegates luck as they prepare to meet next week.

“The global burden of viral hepatitis can be overcome only when the world is united in action.” –Charles Gore, WHA President

World Hepatitis Summit

Mr. Luster Goes to Victoria

Mr. Luster Goes to VictoriaCharacters:
Setting:

Monday, July 21, at the BC Legislative Buildings, Victoria, BC.

Plot:

Daryl Luster went to Victoria on Monday for a full day of meetings with government officials and was warmly welcomed. He left Victoria feeling that the day included some good discussions and was very worthwhile.

Themes and Topics Discussed During Mr. Daryl Luster’s Meetings:
  • Treatment as prevention (TasP) shouldn’t be considered as the main or only way to change hepatitis C in BC. In the drive to cure individuals and eradicate hepatitis C in BC, strategies against hep C must be specifically designed to meet the needs of specific populations.
  • The impact of baby boomers with hep C on the health system.
  • The opportunity the new medications provided for disease elimination.
  • The need for more resources for awareness, screening, and for a coordinated strategy.

Mr. Smith Goes to Washington is a significant picture. It is significant because it emphasis democracy in action. I consider it a real privilege and a real experience to have played even a minor part.” ~1939 Mr Smith goes to Washington Trailer 

Daryl Luster